Key result
In patients with newly diagnosed type 2 diabetes, the prevalence of confirmed cardiovascular autonomic neuropathy was 1.8% and early cardiovascular autonomic neuropathy was 15.3%.
Cohort (n=557)
Answers are grounded in this paper and cite their sources.
Cardiovascular autonomic neuropathy is present in a notable proportion of patients at the time of type 2 diabetes diagnosis, suggesting the potential value of early standardized screening.
OBJECTIVE: Cardiovascular autonomic diabetic neuropathy (CAN) is a serious complication of diabetes. No reliable data on the prevalence of CAN among patients with newly diagnosed type 2 diabetes are available. Therefore, the aim of this study was to estimate the prevalence of CAN among patients with newly diagnosed type 2 diabetes. RESEARCH DESIGN AND METHODS: A cohort of 557 patients with newly diagnosed type 2 diabetes with cardiovascular autonomic test results available was selected. Early and confirmed neuropathy were assessed using a standardized methodology and their prevalences determined. A multivariate logistic regression analysis was modeled to study the factors associated with CAN. RESULTS: In the entire cohort, the prevalence of confirmed CAN was 1.8%, whereas that of early CAN was 15.3%. Prevalence did not differ between men and women. In the multivariate analyses BMI results were independently and significantly associated with CAN after adjusting for age, sex, hemoglobin A1c, pulse pressure, triglyceride-to-HDL cholesterol ratio, kidney function parameters, and antihypertensive treatment. CONCLUSIONS: CAN could be detected very early in type 2 diabetes. This study may suggest the importance of performing standardized cardiovascular autonomic tests after diagnosis of type 2 diabetes.
No takes yet. Share an insight, caveat, or question.
Zoppini et al. (2015) conducted a cohort in Newly diagnosed type 2 diabetes (n=557). Newly diagnosed type 2 diabetes was evaluated on Confirmed cardiovascular autonomic neuropathy (CAN). In patients with newly diagnosed type 2 diabetes, the prevalence of confirmed cardiovascular autonomic neuropathy was 1.8% and early cardiovascular autonomic neuropathy was 15.3%.
Synapse has enriched 10 related papers. Consider them for comparative context: